China’s Benign Prostatic Hyperplasia Treatment Market, estimated at US$ XX billion in 2024 and 2025, is projected to grow steadily at a CAGR of XX% from 2025 to 2030, ultimately reaching US$ XX billion by 2030.
The global market for surgical treatment of benign prostatic hyperplasia (BPH) was valued at $11.92 billion in 2023, reached $12.62 billion in 2024, and is projected to grow at a strong 5.3% CAGR, reaching $17.19 billion by 2030.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374
Drivers
The China Benign Prostatic Hyperplasia (BPH) Treatment Market is experiencing significant growth, primarily fueled by the country’s rapidly expanding elderly population. As BPH is strongly correlated with age, the increasing number of men over 60 directly translates into a higher incidence of the condition and greater demand for effective treatments, including both pharmaceutical and surgical interventions. The rising awareness of urological health among the Chinese male population and improvements in healthcare infrastructure, especially in tier-two and tier-three cities, are also crucial drivers. These developments facilitate earlier diagnosis and broader accessibility to advanced treatment options. Furthermore, government initiatives to modernize healthcare services and increase medical insurance coverage, which includes BPH treatments, are supporting market expansion by making therapies more affordable. There is also an accelerating trend toward adopting technologically advanced and minimally invasive surgical procedures, driven by patient preference for reduced recovery times and better clinical outcomes. The pharmaceutical segment, particularly the use of alpha-blockers and 5-alpha-reductase inhibitors, maintains a strong presence due to the prevalence of mild to moderate cases and is further supported by the introduction of generic and domestically manufactured drugs, ensuring a continuous and growing market.
Restraints
Despite the strong demand, the China Benign Prostatic Hyperplasia Treatment Market is constrained by several factors. A major impediment is the high cost associated with advanced surgical equipment and procedures, particularly for technologically intensive treatments like laser and robotic surgery, which limits their accessibility, especially in smaller or public hospitals with tighter budgets. Furthermore, there is a limited understanding of urological health and a reluctance among certain segments of the male population in China to seek medical help for BPH symptoms due to traditional cultural taboos and privacy concerns, leading to delayed diagnosis and treatment. The market also faces restraints related to adverse side effects associated with long-term drug-based treatments (like alpha-blockers and 5-alpha-reductase inhibitors), which can deter some patients from initiating or continuing therapy. Another challenge is the inconsistent distribution of high-quality medical resources across China; while large urban centers boast state-of-the-art facilities, access to specialized BPH care and skilled urologists remains limited in vast rural areas. This uneven distribution of expertise and technology collectively slows the overall adoption rate of newer, more effective BPH treatments nationwide.
Opportunities
Substantial opportunities exist in the China Benign Prostatic Hyperplasia Treatment Market, largely centering on the clear shift towards minimally invasive procedures (MIPs). This trend provides a fertile environment for devices utilizing technologies such as prostatic urethral lift (PUL), holmium laser enucleation of the prostate (HoLEP), and water vapor thermal therapy, offering superior patient outcomes, shorter hospital stays, and lower costs compared to traditional surgery. The increasing investment in healthcare infrastructure, particularly the development of Ambulatory Surgery Centers (ASCs) and specialized clinics, opens new avenues for market players to deploy advanced BPH solutions outside major hospitals. Moreover, the integration of traditional Chinese medicine (TCM) therapies, such as acupuncture and herbal remedies, alongside Western treatments, presents a unique market opportunity to appeal to a broader patient demographic seeking complementary or alternative care options. The push for personalized medicine through advancements in diagnostics and biomarkers offers an opportunity to tailor drug and surgical selection, potentially improving treatment efficacy and patient satisfaction. Finally, leveraging digital health solutions and remote patient monitoring can enhance follow-up care and management for BPH patients, especially those in remote areas, significantly expanding the reach of specialized care.
Challenges
The China BPH Treatment Market is confronted by several key challenges that hinder widespread and efficient adoption of advanced care. One persistent challenge is the need for greater standardization and clinical validation of both new surgical techniques and traditional herbal medicine interventions to meet stringent modern regulatory requirements. Regulatory complexity, particularly concerning the approval and market entry of novel medical devices and drugs, can be time-consuming and expensive for manufacturers. Furthermore, educating the massive patient base and overcoming cultural barriers related to discussing urological problems remain critical challenges that require public health campaigns and improved doctor-patient communication. A practical obstacle is the imperative to train and retain a sufficient number of skilled urologists and technicians capable of operating advanced surgical systems (e.g., robotic and laser platforms), as current expertise is heavily concentrated in major city hospitals. Addressing the high upfront capital expenditure for purchasing and installing advanced BPH treatment systems is also necessary to encourage adoption in more public and regional medical institutions. Successfully navigating these technical, cultural, and economic hurdles is paramount for maximizing the market’s potential and improving BPH care across China.
Role of AI
Artificial Intelligence (AI) is poised to play a transformative role in the China Benign Prostatic Hyperplasia Treatment Market, primarily by enhancing diagnostic precision, optimizing treatment planning, and personalizing patient care pathways. AI algorithms can be applied to analyze vast amounts of medical imaging data (such as ultrasound and MRI scans) to accurately measure prostate volume, identify transitional zone characteristics, and predict the potential success of various treatment modalities (e.g., medical vs. surgical). In drug therapy, AI can process patient comorbidity data and physiological responses to predict the efficacy and potential side effects of alpha-blockers or 5-alpha-reductase inhibitors, leading to more tailored pharmaceutical regimens. Furthermore, AI-driven surgical planning can simulate procedural outcomes, assisting urologists in optimizing laser resection parameters or guiding minimally invasive procedures to reduce surgical time and improve precision. Machine learning models can also be utilized for predictive monitoring, identifying patients at high risk of acute urinary retention or disease progression, allowing for proactive intervention. This integration of AI will not only improve clinical decision-making but also help standardize care protocols across different hospital settings, bridging the quality gap between urban and rural centers.
Latest Trends
Several dynamic trends are currently shaping the China Benign Prostatic Hyperplasia Treatment Market. A dominant trend is the rapid adoption of minimally invasive surgical treatments (MIPs), moving away from traditional transurethral resection of the prostate (TURP). This includes the growing popularity of laser therapies like HoLEP and ThuLEP, as well as emerging, next-generation procedures such as water vapor therapy (Rezum) and prostatic urethral lift (UroLift), which minimize invasiveness and reduce recovery time. Another significant trend is the increasing focus on combination pharmacological therapies, where different classes of drugs (e.g., alpha-blockers and 5-alpha-reductase inhibitors) are used together to address both storage and voiding symptoms more effectively. Furthermore, domestic manufacturing and innovation in BPH treatment devices are surging, supported by “Made in China” policies, aiming to replace expensive imported technology with more cost-effective domestic alternatives while maintaining quality standards. The integration of digital health and telemedicine platforms is becoming a critical trend for remote consultation and follow-up, offering convenience for the large patient population. Finally, research into novel, non-traditional therapies, including the formal study and standardization of specific Chinese herbal medicines and acupuncture for BPH, represents a unique trend seeking to integrate traditional practices into modern clinical guidelines.